Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04555811
Title FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota

diffuse large B-cell lymphoma

B-cell lymphoma


FT596 + Rituximab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.